Tuberculosis vaccines: current status and future prospects

Bibliography Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

• KOCHI A: The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle. (1991) 72:1-6.
   PubMedGoogle Scholar
• RUSSELL S: The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am. J. Trop. Med. Hyg. (2004) 71:147-155.
   PubMed Web of Science ®Google Scholar
• CORBETT EL, WATT CJ, WALKER N et al.: The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. (2003) 163:1009-1021.
   PubMed Web of Science ®Google Scholar
• DYE C, WATT CJ, BLEED DM, HOSSEINI SM, RAVIGLIONE MC: Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA (2005) 293:2767-2775.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ N, HANSEN NI, HOPEWELL PC et al.: Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. Ann. Intern. Med. (1997) 126:123-132.
   PubMed Web of Science ®Google Scholar
• WHALEN C, HORSBURGH CR, HOM D et al.: Accelerated course of human immunodeficiency virus infection after tuberculosis. Am. J. Respir. Crit. Care Med. (1995) 151:129-135.
   PubMed Web of Science ®Google Scholar
• SONNENBERG P, GLYNN JR, FIELDING K et al.: How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J. Infect. Dis. (2005) 191:150-158.
   PubMed Web of Science ®Google Scholar
• BALTUSSEN R, FLOYD K, DYE C: Cost effectiveness analysis of strategies for tuberculosis control in developing countries. Br. Med. J. (2005) 331:1364.
   PubMed Web of Science ®Google Scholar
• BEHR MA, WILSON MA, GILL WP et al.: Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science (1999) 284:1520-1523.
   PubMed Web of Science ®Google Scholar
• COLDITZ GA, BREWER TF, BERKEY CS et al.: Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA (1994) 271:698-702.
   PubMed Web of Science ®Google Scholar
• BREWER TF, COLDITZ GA: Relationship between Bacille Calmette–Guerin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin. Infect. Dis. (1995) 20:126-135.
   PubMed Web of Science ®Google Scholar
• WILSON ME, FINEBERG HV, COLDITZ GA: Geographic latitude and the efficacy of Bacillus Calmette–Guerin vaccine. Clin. Infect. Dis. (1995) 20:982-991.
   PubMed Web of Science ®Google Scholar
• BARRETO ML, CUNHA SS, PEREIRA SM et al.: Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int. J. Tuberc. Lung Dis. (2005) 9:1171-1173.
   PubMed Web of Science ®Google Scholar
• BRANDT L, FEINO CUNHA J, WEINREICH OLSEN A et al.: Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. (2002) 70:672-678.
   PubMed Web of Science ®Google Scholar
• LEUNG CC, TAM CM, CHAN SL et al.: Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. Int. J. Tuberc. Lung Dis. (2001) 5:717-723.
   PubMed Web of Science ®Google Scholar
• RODRIGUES LC, PEREIRA SM, CUNHA SS et al.: Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet (2005) 366:1290-1295.
   PubMed Web of Science ®Google Scholar
• GOMES MG, FRANCO AO, GOMES MC, MEDLEY GF: The reinfection threshold promotes variability in tuberculosis epidemiology and vaccine efficacy. Proc. Biol. Sci. (2004) 271:617-623.
   PubMed Web of Science ®Google Scholar
• GELUK A, VAN MEIJGAARDEN KE, FRANKEN KL et al.: Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans. J. Immunol. (2000) 165:6463-6471.
   PubMed Web of Science ®Google Scholar
• MUTIS T, CORNELISSE YE, OTTENHOFF TH: Mycobacteria induce CD4+ T cells that are cytotoxic and display TH1-like cytokine secretion profile: heterogeneity in cytotoxic activity and cytokine secretion levels. Eur. J. Immunol. (1993) 23:2189-2195.
   PubMed Web of Science ®Google Scholar
• ALTARE F, DURANDY A, LAMMAS D et al.: Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science (1998) 280:1432-1435.
   PubMed Web of Science ®Google Scholar
• JOUANGUY E, ALTARE F, LAMHAMEDI S et al.: Interferon-gamma-receptor deficiency in an infant with fatal Bacille Calmette–Guerin infection. N. Engl. J. Med. (1996) 335:1956-1961.
   PubMed Web of Science ®Google Scholar
• KAUFMANN SH: How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. (2001) 1:20-30.
   PubMed Web of Science ®Google Scholar
• HUYGEN K, CONTENT J, DENIS O et al.: Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. (1996) 2:893-898.
   PubMed Web of Science ®Google Scholar
• TASCON RE, COLSTON MJ, RAGNO S et al.: Vaccination against tuberculosis by DNA injection. Nat. Med. (1996) 2:888-892.
   PubMed Web of Science ®Google Scholar
• MAYO RE, STANFORD JL: Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97. Trans. R. Soc. Trop. Med. Hyg. (2000) 94:563-568.
   PubMed Web of Science ®Google Scholar
• DE BRUYN G, GARNER P: Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst. Rev. (2003):CD001166.
   Google Scholar
• MWINGA A, NUNN A, NGWIRA B et al.: Mycobacterium vaccae (SRL-172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet (2002) 360:1050-1055.
   PubMed Web of Science ®Google Scholar
• WILLIAMS A, HATCH GJ, CLARK SO et al.: Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) (2005) 85:29-38.
   PubMed Web of Science ®Google Scholar
• SAMBANDAMURTHY VK, JACOBS WR Jr: Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect. (2005) 7:955-961.
   PubMed Web of Science ®Google Scholar
• SAMBANDAMURTHY VK, DERRICK SC, JALAPATHY KV et al.: Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect. Immun. (2005) 73:1196-1203.
   PubMed Web of Science ®Google Scholar
• LUDWICZAK P, GILLERON M, BORDAT Y et al.: Mycobacterium tuberculosis phoP mutant: lipoarabinomannan molecular structure. Microbiology (2002) 148:3029-3037.
   PubMed Web of Science ®Google Scholar
• KAMATH AT, FRUTH U, BRENNAN MJ et al.: New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine (2005) 23:3753-3761.
   PubMed Web of Science ®Google Scholar
• HORWITZ MA: Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect. (2005) 7:947-954.
   PubMed Web of Science ®Google Scholar
• HORWITZ MA, HARTH G, DILLON BJ, MASLESA-GALIC S: Recombinant Bacillus Calmette–Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA (2000) 97:13853-13858.
   PubMed Web of Science ®Google Scholar
• HORWITZ MA, HARTH G: A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. (2003) 71:1672-1679.
   PubMed Web of Science ®Google Scholar
• SKEIKY YA, ALDERSON MR, OVENDALE PJ et al.: Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. (2004) 172:7618-7628.
   PubMed Web of Science ®Google Scholar
• BRANDT L, SKEIKY YA, ALDERSON MR et al.: The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. (2004) 72:6622-6632.
   PubMed Web of Science ®Google Scholar
• LANGERMANS JA, DOHERTY TM, VERVENNE RA et al.: Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine (2005) 23:2740-2750.
   PubMed Web of Science ®Google Scholar
• MAZUREK GH, JEREB J, LOBUE P et al.: Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm. Rep. (2005) 54:49-55.
   PubMedGoogle Scholar
• MCSHANE H, PATHAN AA, SANDER CR et al.: Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. (2004) 10:1240-1244.
   PubMed Web of Science ®Google Scholar
• MAYR A, STICKL H, MULLER HK, DANNER K, SINGER H: [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author’s transl)]. Zentralbl Bakteriol [B] (1978) 167:375-390.
   PubMedGoogle Scholar
• MEYER H, SUTTER G, MAYR A: Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. (1991) 72(Pt 5):1031-1038.
   PubMed Web of Science ®Google Scholar
• HARRER E, BAUERLE M, FERSTL B et al.: Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir. Ther. (2005) 10:285-300.
   PubMed Web of Science ®Google Scholar
• STITTELAAR KJ, KUIKEN T, DE SWART RL et al.: Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 19:3700-3709.
   PubMed Web of Science ®Google Scholar
• MOORTHY VS, IMOUKHUEDE EB, MILLIGAN P et al.: A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med (2004) 1:e33.
   PubMedGoogle Scholar
• SMITH CL, DUNBAR PR, MIRZA F et al.: Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int. J. Cancer (2005) 113:259-266.
   PubMed Web of Science ®Google Scholar
• GUPTA UD, KATOCH VM: Animal models of tuberculosis. Tuberculosis (Edinb) (2005) 85:277-293.
   PubMed Web of Science ®Google Scholar
• ORME IM: Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine (2006) 24:2-19.
   PubMed Web of Science ®Google Scholar
• ORME IM: A mouse model of the recrudescence of latent tuberculosis in the elderly. Am. Rev. Respir. Dis. (1988) 137:716-718.
   PubMedGoogle Scholar
• BURKE DS: Of postulates and peccadilloes: Robert Koch and vaccine (tuberculin) therapy for tuberculosis. Vaccine (1993) 11:795-804.
   PubMed Web of Science ®Google Scholar
• BRENNAN MJ, MORRIS SL, SIZEMORE CF: Tuberculosis vaccine development: research, regulatory and clinical strategies. Expert Opin. Biol. Ther. (2004) 4:1493-1504.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-JUARRERO M, TURNER J, BASARABA RJ, BELISLE JT, ORME IM: Florid pulmonary inflammatory responses in mice vaccinated with Antigen-85 pulsed dendritic cells and challenged by aerosol with Mycobacterium tuberculosis. Cell Immunol. (2002) 220:13-19.
   PubMed Web of Science ®Google Scholar
• MOREIRA AL, TSENOVA L, AMAN MH et al.: Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect. Immun. (2002) 70:2100-2107.
   PubMed Web of Science ®Google Scholar
• ORME IM: Safety issues regarding new vaccines for tuberculosis, with an emphasis on post-exposure vaccination. Tuberculosis (Edinb) (2006) 86:68-73.
   PubMed Web of Science ®Google Scholar
• REECE ST, STRIDE N, OVENDALE P, REED SG, CAMPOS-NETO A: Skin test performed with highly purified Mycobacterium tuberculosis recombinant protein triggers tuberculin shock in infected guinea pigs. Infect. Immun. (2005) 73:3301-3306.
   PubMed Web of Science ®Google Scholar
• TAYLOR JL, ORDWAY DJ, TROUDT J et al.: Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA. Infect. Immun. (2005) 73:5189-5193.
   PubMed Web of Science ®Google Scholar
• TURNER OC, ROBERTS AD, FRANK AA et al.: Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the Hsp60 molecule of Mycobacterium tuberculosis. Infect. Immun. (2000) 68:3674-3679.
   PubMed Web of Science ®Google Scholar
• TAYLOR JL, TURNER OC, BASARABA RJ et al.: Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect. Immun. (2003) 71:2192-2198.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: BCG vaccine. WHO position paper. Wkly Epidemiol. Rec. (2004) 79:27-38.
   PubMedGoogle Scholar
• LANG T, HILL AV, MCSHANE H et al.: New TB vaccine granted orphan drug status. Br. Med. J. (2005) 331:1476.
   PubMed Web of Science ®Google Scholar
• MACGREGOR RR, BOYER JD, UGEN KE et al.: First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. (1998) 178:92-100.
   PubMed Web of Science ®Google Scholar
• WANG R, DOOLAN DL, LE TP et al.: Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 282:476-480.
   PubMed Web of Science ®Google Scholar
• DEMISSIE A, ABEBE M, ASEFFA A et al.: Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of TH1 cytokines and the IL-4 antagonist IL-4δ2. J. Immunol. (2004) 172:6938-6943.
   PubMed Web of Science ®Google Scholar
• HILL PC, BROOKES RH, FOX A et al.: Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in the Gambia. Clin. Infect. Dis. (2004) 38:966-973.
   PubMed Web of Science ®Google Scholar
• MCSHANE H, PATHAN AA, SANDER CR et al.: Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) (2005) 85:47-52.
   PubMed Web of Science ®Google Scholar
• DIETRICH J, AAGAARD C, LEAH R et al.: Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. (2005) 174:6332-6339.
   PubMed Web of Science ®Google Scholar
• CARDONA PJ, AMAT I, GORDILLO S et al.: Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine (2005) 23:1393-1398.
   PubMed Web of Science ®Google Scholar
• LOWRIE DB, TASCON RE, BONATO VL et al.: Therapy of tuberculosis in mice by DNA vaccination. Nature (1999) 400:269-271.
   PubMed Web of Science ®Google Scholar
• EVANS JT, WARD JR, KERN J, JOHNSON ME: A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4. Vaccine (2004) 22:1964-1972.
   PubMed Web of Science ®Google Scholar
• SAMBANDAMURTHY VK, WANG X, CHEN B et al.: A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat. Med. (2002) 8:1171-1174.
   PubMed Web of Science ®Google Scholar